Obsidian Therapeutics (OBX) grants director Heidi Hagen options on 37,653 shares
Rhea-AI Filing Summary
Obsidian Therapeutics, Inc. director Heidi Hagen received a stock option grant covering 37,653 shares of common stock on 2026-08-03. The option has an exercise price of $12.00 per share and expires on 2036-08-02. The shares vest upon the earlier of the one-year anniversary of the grant date or the company’s next annual stockholders’ meeting, subject to her continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Hagen Heidi
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 37,653 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 37,653 shares (Direct)
Footnotes (1)
- F1. The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.
Key Figures
Options granted: 37,653 shares
Exercise price: $12.00 per share
Expiration date: 2036-08-02
+1 more
4 metrics
Options granted
37,653 shares
Stock Option (Right to Buy) awarded to director on 2026-08-03
Exercise price
$12.00 per share
Conversion or exercise price for the stock option grant
Expiration date
2036-08-02
Option term end date for the 37,653-share grant
Underlying shares
37,653 shares
Common stock issuable upon exercise of the reported options
Key Terms
Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 12.0000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares underlying this option shall vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting of stockholders financial
"date of the Issuer's annual meeting of stockholders"
FAQ
What did Obsidian Therapeutics (OBX) director Heidi Hagen receive in this Form 4?
Heidi Hagen received a stock option grant for 37,653 shares of Obsidian Therapeutics common stock at an exercise price of $12.00 per share, expiring on 2036-08-02.
When do Heidi Hagen’s new OBX stock options vest?
The options vest and become exercisable upon the earlier of one year after the grant date or the date of Obsidian Therapeutics’ next annual stockholders’ meeting, provided she continues to serve the company on that vesting date.
How many Obsidian Therapeutics (OBX) options does Heidi Hagen hold after this transaction?
After this transaction, Heidi Hagen holds 37,653 stock options as reported in the filing. These options are exercisable for an equal number of common shares at an exercise price of $12.00 per share, subject to vesting.
Did Heidi Hagen buy or sell any OBX common stock in this Form 4?
No common stock purchases or sales are reported. The Form 4 shows only a grant of stock options, representing an acquisition of derivative securities rather than an open-market buy or sell of Obsidian Therapeutics shares.
What is the significance of the $12.00 exercise price on Heidi Hagen’s OBX options?
The $12.00 exercise price is the price per share Heidi Hagen would pay to purchase Obsidian Therapeutics common stock upon exercising the options, any time before their 2036-08-02 expiration and after the options have vested.
AI-generated analysis. How Rhea-AI works. Not financial advice.
